1. Home
  2. ARMP vs AIIA Comparison

ARMP vs AIIA Comparison

Compare ARMP & AIIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Armata Pharmaceuticals Inc.

ARMP

Armata Pharmaceuticals Inc.

N/A

Current Price

$3.72

Market Cap

199.7M

Sector

Health Care

ML Signal

N/A

Logo AI Infrastructure Acquisition Corp. Class A Ordinary Shares

AIIA

AI Infrastructure Acquisition Corp. Class A Ordinary Shares

N/A

Current Price

$10.33

Market Cap

199.3M

Sector

Finance

ML Signal

N/A

Company Overview

Basic Information
Metric
ARMP
AIIA
Founded
N/A
2025
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Blank Checks
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
199.7M
199.3M
IPO Year
1996
2025

Fundamental Metrics

Financial Performance
Metric
ARMP
AIIA
Price
$3.72
$10.33
Analyst Decision
Strong Buy
Analyst Count
2
0
Target Price
★ $17.50
N/A
AVG Volume (30 Days)
★ 75.1K
32.0K
Earning Date
11-12-2026
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ N/A
EPS
N/A
★ N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
★ N/A
Revenue Growth
N/A
N/A
52 Week Low
$2.75
$9.87
52 Week High
$14.98
$10.40

Technical Indicators

Market Signals
Indicator
ARMP
AIIA
Relative Strength Index (RSI) 55.78 54.34
Support Level $3.38 $10.21
Resistance Level $3.96 $10.34
Average True Range (ATR) 0.36 0.02
MACD 0.11 -0.00
Stochastic Oscillator 93.64 57.14

Price Performance

Historical Comparison
ARMP
AIIA

About ARMP Armata Pharmaceuticals Inc.

Armata Pharmaceuticals Inc is a late clinical-stage biotechnology company focused on the development of high-purity and potent, pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using proprietary bacteriophage-based technology. It has completed three Phase 2 clinical trials to date. The Company operates and manages its business as one reportable operating segment, which is the business of developing pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat acute and chronic bacterial infections using its proprietary bacteriophage-based technology.

About AIIA AI Infrastructure Acquisition Corp. Class A Ordinary Shares

AI Infrastructure Acquisition Corp is a blank check company.

Share on Social Networks: